Overview AZD7268 Safety and Tolerability Study Status: Completed Trial end date: 2010-04-01 Target enrollment: Participant gender: Summary The purpose of this study is to prove the principle that treatment with AZD7268 reduces depressive symptoms in patients with Major Depressive Disorder (MDD) compared with placebo. Phase: Phase 2 Details Lead Sponsor: AstraZenecaTreatments: CitalopramDexetimide